Syncom Formulations (India) Limited
Syncom Formulations (India) Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹126 cr of revenue in its latest quarter (Q1 FY27) and kept 19.8% of sales as profit.
| Segment | FY25 | FY26 | Share |
|---|---|---|---|
| Pharmaceuticals Drugs & formulations | 470 | 516 | 97% → 99% |
| Renting of Property | 4 | 4 | 1% → 1% |
| Trading of Commodities | 8 | 1 | 2% → 0% |
| Total | 482 | 521 |
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
“Syncom Formulations (India) Limited is committed to delivering innovative medicines and vaccines that address the evolving healthcare needs of India and improve the quality of life for millions in the country. Your Company’s broadly diversied portfolio includes a wide range of general medicines that are manufactured locally while also offering vaccines and specialty medicines that are exported.”
“to deliver greater value to Syncom has always stood for delivering affordable, safe and high-quality medicines to society.”
Healthier than 78% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 118–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 38
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in SYNCOMF?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 15%, taken from this company's own revenue trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹126 cr |
| Other Income | ₹8 cr |
| Total Income | ₹133 cr |
| Cost of Materials | ₹59 cr |
| Purchases of Stock-in-Trade | ₹18 cr |
| Inventory Change (±) | ₹-11 cr |
| Employee Benefit Expense | ₹17 cr |
| Finance Costs | ₹24.5 L |
| Depreciation & Amortisation | ₹2 cr |
| Other Expenses | ₹16 cr |
| Total Expenses | ₹101 cr |
| Profit before Tax | ₹32 cr |
| Tax Expense | ₹7 cr |
| Net Profit | ₹25 cr |
| Net margin on total income | 18.6% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 115 cr | 135 cr | 126 cr |
| Total income | 121 cr | 150 cr | 133 cr |
| Expenses | 96 cr | 116 cr | 101 cr |
| Profit before tax | 25 cr | 34 cr | 32 cr |
| Tax | 6 cr | 9 cr | 7 cr |
| Net profit (owners' share) | 19 cr | 25 cr | 25 cr |
| Net margin (owners' share, on revenue) | 16.4% | 18.6% | 19.8% |
| EPS (₹) | 0.23 | 0.27 | 0.26 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,770 | ₹4.25 L cr | 53.3 | 8.9% | 12.3% | — |
| Divi's Laboratories Limited | ₹10,064 | ₹2.67 L cr | 74.1 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,650 | ₹1.77 L cr | 82.7 | 11.6% | 10.7% | — |
| Laurus Labs Limited | ₹2,323 | ₹1.26 L cr | 71.1 | 29.1% | 20.0% | — |
| Zydus Lifesciences Limited | ₹1,241 | ₹1.24 L cr | 33.2 | 13.9% | 11.7% | — |
| Dr. Reddy's Laboratories Limited | ₹1,368 | ₹1.14 L cr | 30.8 | 9.5% | 10.6% | — |
| Cipla Limited | ₹1,397 | ₹1.13 L cr | 32.2 | 9.9% | 11.9% | — |
| Mankind Pharma Limited | ₹2,475 | ₹1.02 L cr | 35.9 | 16.2% | 16.4% | — |
| Aurobindo Pharma Limited | ₹1,695 | ₹97,502 cr | 23.7 | 10.9% | 11.3% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹0.1 / share | 23 Sep 2026 |
| Dividend | ₹0.03 / share | 9 Sep 2022 |
| Dividend | ₹0.02 / share | 21 Sep 2017 |
| Dividend | ₹0.02 / share | 22 Sep 2016 |
| Dividend | ₹0.02 / share | 16 Sep 2015 |
| Dividend | ₹0.02 / share | 18 Sep 2014 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.